Table 1.
Demographic and clinical evaluation from the two participant groups
| Variables | PD ICB− | PD ICB+ | p |
|---|---|---|---|
| N | 18 | 17 | |
| Sex, M/F | 13/5 | 11/6 | 0.72 |
| Age, years | 62.7 ± 10.1 | 60.9 ± 6.6 | 0.17 |
| Disease duration, years | 6.1 ± 4.5 | 5.7 ± 3.2 | 0.99 |
| CES-D | 15.1 ± 7.2 | 16.3 ± 10.3 | 0.89 |
| MDS-UPDRS Part II | 23.2 ± 7.7 | 20.3 ± 7.7 | 0.19 |
| QUIP-RS total | 18.1 ± 11.9 | 36.5 ± 10.1 | <0.0001* |
| ICB symptom distribution (based on semistructured behavioral interview) | |||
| Hobbyism | n/a | 12/17 | |
| Eating | n/a | 11/17 | |
| Sex | n/a | 11/17 | |
| Shopping | n/a | 4/17 | |
| Gambling | n/a | 0/17 | |
| Laterality score (− = left worse, + = right worse) | −3.1 ± 9.6 | −1.8 ± 12.0 | 0.74 |
| Dopamine replacement therapy | |||
| Total LEDD, mg/d | 693.9 ± 406.3 | 673.8 ± 440.0 | 0.69 |
| Agonist single-dose equivalent, mg/d | 135.4 ± 76.4 | 103.9 ± 65.1 | 0.19 |
Data are shown as mean ± SD.
*Indicates uncorrected p < 0.05.
No significant group difference observed in the type of DAgonist prescribed (Table 1-3) or the fraction of LEDD accounted for by DAgonist as opposed to levodopa (p = 0.99; Table 1-1). PET acquisition parameters were similar (Table 1-2).
PD ICB+, PD with symptoms consistent with ICB; PD ICB−, PD without ICBs.